Mar 10, 2026 06:22AM ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners

Mar 9, 2026 08:01AM William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY) following Q4 results

Mar 2, 2026 06:37AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

Dec 29, 2025 08:00AM neffy epinephrine nasal spray wins approval in China

Nov 10, 2025 07:29AM William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY)

Nov 10, 2025 07:28AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

Nov 10, 2025 06:09AM ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c

Nov 4, 2025 07:58AM Roth/MKM Starts ARS Pharmaceuticals Inc (SPRY) at Buy

Oct 8, 2025 08:00AM ARS Pharmaceuticals wins European patent challenge for neffy spray

Sep 29, 2025 04:06PM ARS Pharmaceuticals secures $250 million loan facility for neffy expansion

Sep 26, 2025 09:31AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

Sep 19, 2025 08:01AM ARS Pharmaceuticals gains Japan approval for needle-free epinephrine spray

Sep 4, 2025 09:27AM Roth/MKM Starts ARS Pharmaceuticals Inc (SPRY) at Buy, 'Game Changer for the Epinephrine Market'

Aug 14, 2025 05:50AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

Aug 13, 2025 07:09AM ARS Pharmaceuticals, Inc. (SPRY) Reports In-Line Q2 EPS

Jul 18, 2025 09:26AM U.K. approves ARS Pharmaceuticals' needle-free epinephrine nasal spray

Jun 30, 2025 06:02AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

May 14, 2025 04:13PM ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 1c

May 14, 2025 10:22AM Increasing unusual call option volume: NXT SPRY EXEL SATS SONO FNGR GLL HALO TDUP AMDL

Mar 31, 2025 06:19AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY), PT $32

Mar 24, 2025 05:24AM ARS Pharmaceuticals Inc (SPRY) PT Raised to $32 at Raymond James

Mar 20, 2025 10:06AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY), PT $28

Mar 7, 2025 07:07AM Scotiabank Starts ARS Pharmaceuticals Inc (SPRY) at Sector Outperform

Mar 5, 2025 04:11PM ARS Pharmaceuticals (SPRY) Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis

Jan 6, 2025 08:10AM ARS Pharmaceuticals (SPRY) Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 12, 2024 02:33PM ARS Pharmaceuticals (SPRY) Announces Filings for Approval of neffy in China, Japan and Australia

Nov 11, 2024 07:03AM ARS Pharmaceuticals (SPRY) Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies

Sep 23, 2024 08:12AM ARS Pharmaceuticals (SPRY) Announces U.S. Availability of neffy, the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Sep 9, 2024 04:47PM ARS Pharmaceuticals (SPRY) Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg

Aug 26, 2024 09:31AM ARS Pharmaceuticals (SPRY): EURneffy Approved in EU as First and Only Needle-Free Emergency Treatment of Allergic Reactions

Aug 19, 2024 11:44PM Cantor Fitzgerald Starts ARS Pharmaceuticals Inc (SPRY) at Overweight

Aug 9, 2024 12:50PM ARS Pharmaceuticals (SPRY) Receives FDA Approval of neffy

Aug 7, 2024 04:55AM ARS Pharmaceuticals, Inc. (SPRY) Misses Q2 EPS by 1c

Jun 28, 2024 06:30AM ARS Pharmaceuticals (SPRY) Announces EURneffy Recommended for Approval by CHMP